GenapSys, a Redwood City, Calif.-based provider of next generation sequencing systems, closed a $37m Series B financing.
Backers included existing investors Decheng Capital and IPV Capital and new investors Yuri Milner, Stanford StartX Fund, as well as other private and institutional investors.
The company intends to use the funds to continue to develop its platform through commercialization.
Led by Dr. Hesaam Esfandyarpour, Founder and CEO, GenapSys has created, developed and is producing a Genomic Testing system which integrates advanced fluidics and analytical capabilities.
The company’s first product, the GENIUS™ 110 System, aims to enable customers to replace sample preparation and sequencing bottleneck with a streamlined workflow for Next Generation Sequencing.